KR20040105815A - 항체를 제시하는 단백질 중공 나노입자를 사용하는치료약제 및 단백질 중공 나노입자 - Google Patents
항체를 제시하는 단백질 중공 나노입자를 사용하는치료약제 및 단백질 중공 나노입자 Download PDFInfo
- Publication number
- KR20040105815A KR20040105815A KR10-2004-7015430A KR20047015430A KR20040105815A KR 20040105815 A KR20040105815 A KR 20040105815A KR 20047015430 A KR20047015430 A KR 20047015430A KR 20040105815 A KR20040105815 A KR 20040105815A
- Authority
- KR
- South Korea
- Prior art keywords
- protein
- hbsag
- antibody
- mutated
- particles
- Prior art date
Links
- BUJFTKPQXSIZFX-UHFFFAOYSA-N CCC(C)(C)NC Chemical compound CCC(C)(C)NC BUJFTKPQXSIZFX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (21)
- 특정의 세포 또는 조직에 대한 항체가 제시되고, 입자 형성능을 갖는 단백질로 이루어진 중공 나노입자에, 질환 치료용의 세포 도입 물질이 포함되어 이루어진 약제.
- 제1항에 있어서, 항체가 암특이적 항체 또는 항바이러스성 단백질 항체임을 특징으로하는 약제.
- 제1항 또는 제2항에 있어서, 항체가 입자 형성능을 갖는 단백질에 융합한 ZZ 태그와의 결합에 의해 입자 표면에 제시됨을 특징으로 하는 약제.
- 제1항 또는 제2항에 있어서, 항체가 비오틴 수식된, 입자 형성능을 갖는 단백질에 융합한 스트렙태그와 결합한 스트렙트아비딘 또는 그 유도체와, 상기 비오틴과의 결합에 의해 입자 표면에 제시됨을 특징으로 하는 약제.
- 제1항 또는 제2항에 있어서, 항체가 입자 형성능을 갖는 단백질에 융합한 일본쇄임을 특징으로 하는 약제.
- 제1항 내지 제5항 중의 어느 한 항에 있어서, 입자 형성능을 갖는 단백질로이루어진 중공 나노입자가, 진핵세포에서 발현시킴으로써 수득됨을 특징으로 하는 약제.
- 제6항에 있어서, 진핵세포가 효모, 곤충세포 또는 동물세포중의 어느 하나임을 특징으로 하는 약제.
- 제1항 내지 제7항 중의 어느 한 항에 있어서, 입자 형성능을 갖는 단백질이 돌변변이된 B형 간염 바이러스 표면 항원 단백질임을 특징으로 하는 약제.
- 제8항에 있어서, 돌연변이된 B형 간염 바이러스 표면 항원 단백질이 preS 영역의 아미노산 일부를 결실하도록 돌연변이되어 있음을 특징으로 하는 약제.
- 제8항 또는 제9항에 있어서, 돌연변이된 B형 간염 바이러스 표면 항원 단백질이 혈청형 y 타입이고, pre-S 영역의 전체 아미노산 서열 중, 적어도 N 말단으로부터 1번째 내지 20번째 아미노산 잔기를 보유하도록 돌연변이되어 있음을 특징으로 하는 약제.
- 제10항에 있어서, 돌연변이된 B형 간염 바이러스 표면 항원 단백질이 추가로 pre-S 영역의 전체 아미노산 서열 중, N 말단으로부터 50번째 내지 153번째의 아미노산을 결실하도록 돌연변이되어 있음을 특징으로 하는 약제.
- 제8항 또는 제9항에 있어서, 돌연변이된 B형 간염 바이러스 표면 항원 단백질이 혈청형 d 타입이고, pre-S 영역의 전체 아미노산 서열 중, 적어도 N 말단으로부터 12번째 내지 31번째 아미노산 잔기를 보유하도록 돌연변이되어 있음을 특징으로 하는 약제.
- 제12항에 있어서, 돌연변이된 B형 간염 바이러스 표면 항원 단백질이 추가로 pre-S 영역의 전체 아미노산 서열 중, N 말단으로부터 61번째 내지 164번째의 아미노산을 결실하도록 돌연변이되어 있음을 특징으로 하는 약제.
- 제1항 내지 제13항 중의 어느 한 항에 있어서, 세포 도입 물질이 유전자임을 특징으로 하는 약제.
- 제14항에 있어서, 유전자가 단순 헤르페스바이러스 유래 티미딘키나제(HSV1 tk) 유전자임을 특징으로 하는 약제.
- 제1항 내지 제15항 중의 어느 한 항에 있어서, 정맥 주사에 의해 인체에 투여됨을 특징으로 하는 약제.
- 제1항 내지 제16항 중의 어느 한 항에 기재된 약제를 투여하는 것에 의한 질환의 치료방법.
- 입자 형성능을 갖고, pre-S 영역의 전체 아미노산 서열 중, 적어도 N 말단으로부터 1번째 내지 20번째 아미노산 잔기를 보유하도록 돌연변이된 혈청형 y 타입의 B형 간염 바이러스 표면 항원 단백질로 이루어짐을 특징으로 하는 중공 나노입자.
- 제18항에 있어서, 돌연변이된 B형 간염 바이러스 표면 항원 단백질이 추가로 pre-S 영역의 전체 아미노산 서열 중, N 말단으로부터 50번째 내지 153번째의 아미노산을 결실하도록 돌연변이되어 있음을 특징으로 하는 중공 나노입자.
- 입자 형성능을 갖고, pre-S 영역의 전체 아미노산 서열 중, 적어도 N 말단으로부터 12번째 내지 31번째 아미노산 잔기를 보유하도록 돌연변이된 혈청형 d 타입의 B형 간염 바이러스 표면 항원 단백질로 이루어짐을 특징으로 하는 중공 나노입자.
- 제20항에 있어서, 돌연변이된 B형 간염 바이러스 표면 항원 단백질이 추가로 pre-S 영역의 전체 아미노산 서열 중, N 말단으로부터 61번째 내지 164번째의 아미노산을 결실하도록 돌연변이되어 있음을 특징으로 하는 중공 나노입자.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JPJP-P-2002-00097424 | 2002-03-29 | ||
JP2002097424 | 2002-03-29 | ||
JPJP-P-2003-00045088 | 2003-02-21 | ||
JP2003045088A JP4212921B2 (ja) | 2002-03-29 | 2003-02-21 | 抗体を提示するタンパク質中空ナノ粒子を用いる治療薬剤およびタンパク質中空ナノ粒子 |
PCT/JP2003/003694 WO2003082330A1 (fr) | 2002-03-29 | 2003-03-26 | Medicament therapeutique comprenant des nanoparticules proteiques creuses presentant un anticorps et nanoparticules proteiques creuses |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040105815A true KR20040105815A (ko) | 2004-12-16 |
KR100635870B1 KR100635870B1 (ko) | 2006-10-18 |
Family
ID=28677594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047015430A KR100635870B1 (ko) | 2002-03-29 | 2003-03-26 | 항체를 제시하는 단백질 중공 나노입자를 사용하는치료약제 및 단백질 중공 나노입자 |
Country Status (5)
Country | Link |
---|---|
US (1) | US7951379B2 (ko) |
EP (1) | EP1491210B1 (ko) |
JP (1) | JP4212921B2 (ko) |
KR (1) | KR100635870B1 (ko) |
WO (1) | WO2003082330A1 (ko) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005049824A1 (ja) * | 2003-11-21 | 2005-06-02 | Japan Science And Technology Agency | 生体構造認識部位を提示する中空ナノ粒子およびその生産方法、並びにその利用 |
US20070059746A1 (en) * | 2005-09-14 | 2007-03-15 | Japan Science And Technology Agency | Substance carrier using hollow nanoparticle of hepatitis B virus protein and liposome, and method of introducing substance into cell |
JP2007089440A (ja) * | 2005-09-28 | 2007-04-12 | Kobe Univ | 細胞膜透過ペプチドを提示したナノ粒子による細胞への物質導入 |
WO2008018555A1 (fr) * | 2006-08-11 | 2008-02-14 | National University Corporation Okayama University | PARTICULE HBsAg À FAIBLE ANTIGÉNICITÉ ET SON PROCÉDÉ DE PRODUCTION |
HUE039497T2 (hu) * | 2007-03-07 | 2019-01-28 | Abraxis Bioscience Llc | Rapamicin rákellenes szert és albumint tartalmazó nanorészecske |
EP2262489A2 (en) * | 2008-02-28 | 2010-12-22 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Hollow nanoparticles and uses thereof |
JP2010096677A (ja) * | 2008-10-17 | 2010-04-30 | Toray Ind Inc | 抗体/抗原結合能を有する高感度免疫学測定用ナノ粒子 |
EP2419143B8 (en) | 2009-04-13 | 2018-06-27 | INSERM - Institut National de la Santé et de la Recherche Médicale | Hpv particles and uses thereof |
US9700639B2 (en) | 2012-02-07 | 2017-07-11 | Aura Biosciences, Inc. | Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells |
WO2013147232A1 (ja) * | 2012-03-30 | 2013-10-03 | 国立大学法人名古屋大学 | 樹状細胞表面タンパク質に対する抗体を有するバイオナノカプセル |
ES2917573T3 (es) | 2013-09-18 | 2022-07-08 | Aura Biosciences Inc | Método de producción de moléculas fotosensibles |
MX2018005468A (es) | 2015-10-30 | 2018-11-09 | The Us Secretary Department Of Health And Man Services | Terapia dirigida contra el cáncer. |
AU2020411873A1 (en) | 2019-12-23 | 2022-07-28 | Mitsubishi Tanabe Pharma Corporation | Mutant RSV F protein and use thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08504088A (ja) | 1992-09-17 | 1996-05-07 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 腫瘍特異性抗体および抗原 |
ATE146528T1 (de) * | 1992-09-17 | 1997-01-15 | Merck Patent Gmbh | Kleinzelliger lungenkarzinom-spezifischer antikörper und antigenen |
US7354587B1 (en) * | 1994-07-06 | 2008-04-08 | Immunomedics, Inc. | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
US5798100A (en) * | 1994-07-06 | 1998-08-25 | Immunomedics, Inc. | Multi-stage cascade boosting vaccine |
ES2167391T3 (es) | 1994-09-16 | 2002-05-16 | Merck Patent Gmbh | Inmunoconjugados ii. |
AU721927B2 (en) | 1995-12-22 | 2000-07-20 | Immunomedics Inc. | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
AU3916997A (en) * | 1996-08-19 | 1998-03-06 | Vivorx Pharmaceuticals, Inc. | Methods for the production of protein particles useful for delivery of pharmacological agents |
AU2662999A (en) * | 1998-02-09 | 1999-08-23 | Genzyme Corporation | Nucleic acid delivery vehicles |
JP4085231B2 (ja) | 2000-02-28 | 2008-05-14 | 株式会社ビークル | タンパク質中空ナノ粒子とそれを用いた物質運搬体、ならびに細胞への物質導入方法 |
-
2003
- 2003-02-21 JP JP2003045088A patent/JP4212921B2/ja not_active Expired - Lifetime
- 2003-03-26 US US10/509,249 patent/US7951379B2/en not_active Expired - Fee Related
- 2003-03-26 EP EP03715409.3A patent/EP1491210B1/en not_active Expired - Lifetime
- 2003-03-26 KR KR1020047015430A patent/KR100635870B1/ko active IP Right Grant
- 2003-03-26 WO PCT/JP2003/003694 patent/WO2003082330A1/ja active Application Filing
Also Published As
Publication number | Publication date |
---|---|
KR100635870B1 (ko) | 2006-10-18 |
JP2004002313A (ja) | 2004-01-08 |
US20060088536A1 (en) | 2006-04-27 |
WO2003082330A1 (fr) | 2003-10-09 |
EP1491210B1 (en) | 2013-06-19 |
JP4212921B2 (ja) | 2009-01-21 |
EP1491210A4 (en) | 2010-10-13 |
US7951379B2 (en) | 2011-05-31 |
EP1491210A1 (en) | 2004-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100645851B1 (ko) | 단백질 중공 나노 입자와 그것을 이용한 물질운반체, 및세포로의 물질도입방법 | |
KR100635870B1 (ko) | 항체를 제시하는 단백질 중공 나노입자를 사용하는치료약제 및 단백질 중공 나노입자 | |
KR101455222B1 (ko) | 면역 요법으로서의 효모계 백신 | |
US20090011036A1 (en) | Drug containing hollow protein nanoparticles of particle-forming protein, fused with disease-treating target-cell-substance | |
KR100674325B1 (ko) | 단백질 중공 나노 입자 및 이를 이용한 약제 | |
EP1541135A1 (en) | Hollow nanoparticle having modified cysteine residue and drug with the use thereof | |
WO2003082344A1 (fr) | Remedes a base de nanoparticules proteiques creuses renfermant un facteur de croissance ou analogue | |
AU2003206663B9 (en) | Microorganism for genetic therapeutic treatment of proliferative diseases | |
KR20040095333A (ko) | 단백질 중공 나노입자를 사용한 간질환 치료용 약제 | |
WO2012157945A2 (ko) | 액포 표면에 목적단백질의 발현 방법 및 약물전달체 | |
WO2005049824A1 (ja) | 生体構造認識部位を提示する中空ナノ粒子およびその生産方法、並びにその利用 | |
JP2004277355A (ja) | 血友病治療用薬剤及びそれを用いた血友病治療方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121005 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20130924 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140905 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150907 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160905 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20190905 Year of fee payment: 14 |